《欧洲食品安全局的审查报告没有报告草甘膦的内分泌干扰》

  • 来源专题:食物与营养
  • 编译者: niexiuping
  • 发布时间:2017-09-30
  • 欧洲食品安全局(EFSA)回顾了现有研究和数据主题,发表了其审查和结论在一篇关于“同行审查的农药风险评估潜在内分泌扰乱草甘膦的性质”在9月发行的欧洲食品安全署日报》。目前的结论对现有的EFSA结论进行了后续评估,以获得对草甘膦的批准更新的同行评审(EFSA Journal 2015;13(11):4302)关注与草甘膦潜在内分泌活性相关的突出问题。目前的评估结果表明,证据的重量表明,草甘膦并没有通过雌激素、雄激素、甲状腺或类固醇的行为模式来扰乱内分泌,这是基于毒理学领域的全面数据库。现有的生态系统研究并没有反驳这一结论。

相关报告
  • 《对草甘膦潜在内分泌干扰性质农药风险评估的同行评议》

    • 来源专题:转基因生物新品种培育
    • 编译者:Zhao
    • 发布时间:2017-09-12
    • 欧盟委员会(EC)要求欧洲食品安全局(EFSA)根据欧盟一般食品法(第178/2002号法规)第31条款对农药活性物质--草甘膦,在潜在内分泌活动上的有关信息进行总结。在此背景下,基于由主审国--德国在进行资料评价、起草风险评估,并在提交和评估申请人提供的相关数据之后公开评估报告,并在同行评议此农药活性物质的主要危险评估报告后,欧洲食品安全局(EFSA)形成相应安全评估结论。当前所得到的结论是经同行评议的对之前欧洲食品安全局(EFSA)已得检测结论的进一步检测评估,以更新之前同行评议的关于草甘膦在潜在内分泌相关活动(EFSA Journal 2015; 13(11):4302)未解决问题方面的评估。从目前的评估结论可以看出,在一定程度上,所有证据可以表明:基于毒理学领域的相关数据信息,草甘膦这一活性物质在雌激素,雄激素,甲状腺激素或类固醇的内分泌生成机理中没有干扰作用。此外,目前已有的生态毒素研究与这一结论并不矛盾冲突。
  • 《2003欧洲食品安全局年度报告》

    • 来源专题:食物与营养
    • 编译者:潘淑春
    • 发布时间:2005-03-29
    • In 2003 EFSA got off to a flying start and succeeded in establishing itself as an independent European agency dedicated to improving consumer confidence by providing scientific advice, information and communication on all matters related to food safety. The Executive Director, Geoffrey Podger, took up his appointment in February and the Director of Science and Deputy Executive Director, Herman Koëter, and the Director of Communications, Anne-Laure Gassin, took up their positions in October. There has been substantial recruitment during the year - the staff grew from a very small team to a total of 72 employees by the end of the year. The Advisory Forum, EFSA’s main channel for contact with the Member States, held its inaugural meeting in March and met six times during the year. In order to stimulate interest in EFSA and its work throughout Europe, the Forum has from its inception invited participants from the accession countries and also from Norway, Iceland and Switzerland and it has held most of its meetings in the Member States.